Codagenix Inc. has raised an additional $25 million, bringing its total funding to $45 million, to support its vaccine development efforts. This new round includes contributions from Serum Institute of India and existing investors Euclidean Capital and Adjuvant Capital. The funding will advance phase 1 trials for the CodaVax-RSV vaccine targeting respiratory syncytial virus and the CodaVax-H1N1 influenza vaccine. Codagenix, based at Farmingdale State College’s Broad Hollow Bioscience Park and in Cambridge, Massachusetts, utilizes cutting-edge synthetic biology to create innovative vaccines. The company is also involved in a WHO study of its CoviLiv nasal COVID-19 vaccine.
21
Feb
